Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

797.85INR
17 Oct 2014
Price Change (% chg)

Rs1.00 (+0.13%)
Prev Close
Rs796.85
Open
Rs793.00
Day's High
Rs806.25
Day's Low
Rs792.00
Volume
205,334
Avg. Vol
195,774
52-wk High
Rs877.40
52-wk Low
Rs552.50

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.63
Market Cap (Mil.): Rs1,653,514.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.19

Financials

  SUN.BO Industry Sector
P/E (TTM): 28.12 32.64 33.19
EPS (TTM): 28.39 -- --
ROI: -- 18.40 17.65
ROE: -- 19.06 18.46
Search Stocks

Sun Pharma gains on cash position, receding USFDA risk

Reuters Market Eye - Sun Pharmaceutical Industries gains 3.3 percent.

29 Sep 2014

MARKET EYE -India's Sun Pharma gains on cash position, receding USFDA risk

* Sun Pharmaceutical Industries gains 3.3 percent. * Adds to Friday's 4.2 percent surge. * Strong cash position, receding U.S. FDA risk seen as main reasons for gains. * Company had cash and cash equivalents of 75.90 billion rupees as on March 31, 2014, annual report shows. * Gains also helped as rupee weakens, which would help boost returns from overseas markets. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

29 Sep 2014

Sun Pharma head towards biggest daily gain in 5-1/2 months

Reuters Market Eye - Sun Pharmaceutical Industries gains more than 6 percent.

26 Sep 2014

MARKET EYE -India's Sun Pharma gains; becomes first to license drug from innovator

* Sun Pharmaceutical Industries gains 2 percent. * Merck & Co Inc said it had licensed its experimental psoriasis drug to Sun. * First instance of an Indian company taking global rights for a novel drug, traders say. * Deal strengthens Sun's presence in the U.S. skin market, also boosts revenue potential, traders add. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

18 Sep 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

Sun's takeover of Ranbaxy may hurt competition - CCI

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

India regulator says Sun's takeover of Ranbaxy may hurt competition

MUMBAI, Sept 4 - India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

04 Sep 2014

Sun Pharma posts Q1 profit on strong U.S. sales

MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.

13 Aug 2014

Sun Pharma gains after earnings beat estimates

Reuters Market Eye - Sun Pharmaceutical Industries gains 1.6 percent after June-quarter earnings beat estimates on higher U.S. sales.

13 Aug 2014

Earnings vs. Estimates

Search Stocks